Cladribine, Low-Dose Cytarabine (LDAC), and Venetoclax (VEN) in Older/Unfit Acute Myeloid Leukemia (AML) Patients: A Single-Institution Experience

被引：0
|
作者：
Yohannan, Binoy [1 ]
Khan, Hina [1 ]
Cervoni-Curet, Frances [1 ]
Rios, Adan [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
AML; cladribine; low-dose cytarabine; older/unfit AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-100
引用
收藏
页码：S267 / S267
页数：1
相关论文
共 50 条
  • [31] Low-dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia
    Rong, Chunmeng
    Yang, Fang
    Chen, Yalu
    Wang, Ming
    Ai, Cheng
    Luo, Yuqing
    Gao, Panpan
    Weng, Yiqin
    Huang, Xiaguang
    Gu, Meier
    Huang, Weiping
    Xia, Yongming
    ONCOLOGY LETTERS, 2024, 27 (05)
  • [32] Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Laloi, Louise
    Billotey, Natacha Chaumard
    Dumas, Pierre-Yves
    Paul, Franciane
    Villate, Alban
    Simand, Celestine
    Fornecker, Luc
    Puisset, Florent
    Bertoli, Sarah
    Simonet, Marion Boissard
    Laribi, Kamel
    Houyou, Dyhia
    Santagostino, Alberto
    Michel, Claire
    Guepin, Gabrielle Roth
    Guerineau, Elodie
    Tabrizi, Reza
    Hunault, Mathilde
    Giltat, Aurelien
    Kaphan, Eleonore
    Bulabois, Claude
    Cartet, Elodie
    Rocher, Clement
    Lachenal, Florence
    Morisset, Stephane
    Recher, Christian
    Pigneux, Arnaud
    Belhabri, Amine
    Michallet, Mauricette
    Michallet, Anne-Sophie
    CANCER MEDICINE, 2023, 12 (06): : 7175 - 7181
  • [33] ORAL IDARUBICIN AND LOW-DOSE CYTARABINE AS THE INITIAL TREATMENT OF ACUTE MYELOID-LEUKEMIA IN ELDERLY PATIENTS
    HAROUSSEAU, JL
    HUGUET, F
    REIFFERS, J
    COLLOMBAT, P
    KOHSER, P
    LEPRISE, PY
    SOUTEYRAND, P
    HURTELOUP, P
    LEUKEMIA & LYMPHOMA, 1991, 5 (2-3) : 145 - 149
  • [34] Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
    Loges, Sonja
    Heuser, Michael
    Chromik, Joerg
    Sutamtewagul, Grerk
    Kapp-Schwoerer, Silke
    Crugnola, Monica
    Di Renzo, Nicola
    Lemoli, Roberto
    Mattei, Daniele
    Fiedler, Walter
    Alvarado-Valero, Yesid
    Ben-Batalla, Isabel
    Waizenegger, Jonas
    Rieckmann, Lisa-Marie
    Janning, Melanie
    Collienne, Maike
    Imbusch, Charles D.
    Beumer, Niklas
    Micklem, David
    Nilsson, Linn
    Madeleine, Noelly
    Mccracken, Nigel
    Oliva, Cristina
    Gorcea-Carson, Claudia
    Gjertsen, Bjorn T.
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [35] Single low-dose decitabine as frontline therapy of acute myeloid leukaemia, with venetoclax salvage
    Jitaru, Ciprian
    Peters, Mareike Cathrina
    Aggarwal, Lovisha
    Bancos, Anamaria
    Tigu, Adrian Bogdan
    Cenariu, Diana
    Selicean, Cristina
    Pasca, Sergiu
    Moisoiu, Vlad
    Rotariu, Petra
    Santa, Maria
    Iluta, Sabina
    Drula, Rares
    Kegyes, David
    Kurtus, Aranka
    Zdrenghea, Mihnea
    Gondek, Lukasz
    Tomuleasa, Ciprian
    Ghiaur, Gabriel
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (20)
  • [36] The Response to Induction Therapy Is Crucial for the Treatment Outcomes of Elderly Patients with Acute Myeloid Leukemia: Single-institution Experience
    Tasaki, Toshiki
    Yamauchi, Takahiro
    Matsuda, Yasufumi
    Takai, Mihoko
    Ookura, Miyuki
    Lee, Shin
    Tai, Katsunori
    Ikegaya, Satoshi
    Kishi, Shinji
    Yoshida, Akira
    Urasaki, Yoshimasa
    Iwasaki, Hiromichi
    Ueda, Takanori
    ANTICANCER RESEARCH, 2014, 34 (10) : 5631 - 5636
  • [37] Clofarabine and Low-Dose Cytarabine Combination in Relapsed/Refractory Acute Myeloid Leukemia Patients with High Risk Features
    Vigil, Carlos
    Jahan, Nusrat
    Paun, Oana
    Weis, Jennifer
    Heckman, Kevin
    Silverman, Margarida
    Carter, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S297 - S297
  • [38] A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia
    Burnett, A. K.
    Russell, N.
    Hills, R. K.
    Panoskaltsis, N.
    Khwaja, A.
    Hemmaway, C.
    Cahalin, P.
    Clark, R. E.
    Milligan, D.
    LEUKEMIA, 2015, 29 (06) : 1312 - 1319
  • [39] Low-dose Cytarabine plus Aclarubicin for Patients with Previously Untreated Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Ineligible for Standard-dose Cytarabine plus Anthracycline
    Fukushima, Toshihiro
    Kawabata, Hiroshi
    Sawaki, Toshioki
    Satoh, Tomomi
    Nakamura, Takuji
    Iwao, Haruka
    Nakajima, Akio
    Sakai, Tomoyuki
    Miki, Miyuki
    Fujita, Yoshimasa
    Tanaka, Masao
    Kawanami, Takafumi
    Masaki, Yasufumi
    Okazaki, Toshiro
    Umehara, Hisanori
    ANTICANCER RESEARCH, 2012, 32 (04) : 1347 - 1353
  • [40] A Single Institution Experience on Clinical Outcomes of TP-53 Mutant Acute Myeloid Leukemia (AML)
    Yohannan, Binoy
    Cervoni-Curet, Frances
    Rios, Adan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S223 - S223
12345